Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
Scholar Rock Holding Corporation (SRRK)
Last scholar rock holding corporation earnings: 11/12 07:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Preliminary PK/PD data from a subset of patients are anticipated by year-end 2019 Interim safety and efficacy analysis of a subset of patients with six months of treatment expected in 1H20; top-line results for the full 12-month treatment period are expected beginning 4Q20 CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the initiation of patient dosing in the Phase 2 clinical trial of SRK-015, a highly specific inhibitor of myostatin activation, in Type 2 and Type 3 Spinal Muscular Atrophy (SMA). All patients will receive SRK-015 once every four weeks either as a monotherapy or in conjunction with an approved SMN upregulator therapy. This Ph
Show less
Read more
Impact Snapshot
Event Time:
SRRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRRK alerts
High impacting Scholar Rock Holding Corporation news events
Weekly update
A roundup of the hottest topics
SRRK
News
- Scholar Rock Holding Co. (NASDAQ: SRRK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Scholar Rock Holding Co. (NASDAQ: SRRK) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.MarketBeat
- Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress [Yahoo! Finance]Yahoo! Finance
- Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business ProgressBusiness Wire
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
SRRK
Earnings
- 11/7/23 - In-Line
SRRK
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/29/24 - Form ARS
- SRRK's page on the SEC website